Sygnature Discovery Overview
- Year Founded
-
2004
- Status
-
Private
- Employees
-
1,000
- Latest Deal Type
-
Debt - Acquisition
- Financing Rounds
-
5
- Investments
-
10
Sygnature Discovery General Information
Description
Provider of integrated drug discovery resources and expertise intended to accelerate clients' research activities in creating better drugs for patients with unmet medical needs. The company offers intellectual input and drug discovery expertise to accelerate target validation, hit identification, hit-to-lead, lead optimization and drug discovery programs with capabilities including medicinal chemistry, in vitro biology, computational chemistry and informatics and protein crystallography, assisting clients in drug discovery projects through pre-clinical candidates.
Contact Information
Website
www.sygnaturediscovery.comCorporate Office
- BioCity
- Pennyfoot Street
- Nottingham NG1 1GR
- England, United Kingdom
Corporate Office
- BioCity
- Pennyfoot Street
- Nottingham NG1 1GR
- England, United Kingdom
Sygnature Discovery Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Sygnature Discovery Comparisons
Industry
Financing
Details
Sygnature Discovery Competitors (53)
One of Sygnature Discovery’s 53 competitors is Domainex, a Venture Capital-Backed company based in Saffron Walden, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Domainex | Venture Capital-Backed | Saffron Walden, United Kingdom | ||||
| Rho | Corporation | Durham, NC | ||||
| Verge Genomics | Venture Capital-Backed | South San Francisco, CA | ||||
| Recursion Pharmaceuticals | Formerly VC-backed | Salt Lake City, UT | ||||
| X-37 | Venture Capital-Backed | South San Francisco, CA |
Sygnature Discovery Patents
Sygnature Discovery Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250066300-A1 | 3-(2-(dimethylamino)ethyl)-1h-indol-4-yl oligomeric derivatives | Pending | 25-Aug-2023 | ||
| US-20250066394-A1 | 3-(2-(dimethylamino)ethyl)-1h-indol-4-yl derivatives | Pending | 25-Aug-2023 | ||
| US-11773063-B1 | Pharmaceutically acceptable salts and compositions thereof | Active | 19-Aug-2022 | ||
| US-20240101514-A1 | Pharmaceutically acceptable salts and compositions thereof | Active | 19-Aug-2022 | ||
| US-12264131-B2 | Pharmaceutically acceptable salts and compositions thereof | Active | 19-Aug-2022 | C07D209/16 |
Sygnature Discovery Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Sygnature Discovery Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Sygnature Discovery Investments (10)
Sygnature Discovery’s most recent deal was a Buyout/LBO with NuChem Sciences. The deal was made on 31-Jul-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| NuChem Sciences | 31-Jul-2023 | Buyout/LBO | BPO/Outsource Services | ||
| SB Drug Discovery | 17-Jan-2023 | Buyout/LBO | Drug Discovery | ||
| Peak Proteins | 12-Apr-2022 | Buyout/LBO | Biotechnology | ||
| XenoGesis | 24-Sep-2020 | Buyout/LBO | Drug Discovery | ||
| Alderley Oncology | 03-Jun-2020 | Buyout/LBO | Laboratory Services (Healthcare) |
Sygnature Discovery Affiliates
Subsidiaries (5)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Peak Proteins | Macclesfield, United Kingdom | 2014 | |
| NuChem Sciences | Saint-Laurent, Canada | 2011 | |
| XenoGesis | Nottingham, United Kingdom | 2011 | |
| RenaSci | Nottingham, United Kingdom | 2001 | |
| SB Drug Discovery | Glasgow, United Kingdom | 1994 |
Sygnature Discovery FAQs
-
When was Sygnature Discovery founded?
Sygnature Discovery was founded in 2004.
-
Where is Sygnature Discovery headquartered?
Sygnature Discovery is headquartered in Nottingham, United Kingdom.
-
What is the size of Sygnature Discovery?
Sygnature Discovery has 1,000 total employees.
-
What industry is Sygnature Discovery in?
Sygnature Discovery’s primary industry is Drug Discovery.
-
Is Sygnature Discovery a private or public company?
Sygnature Discovery is a Private company.
-
What is Sygnature Discovery’s current revenue?
The current revenue for Sygnature Discovery is .
-
Who are Sygnature Discovery’s investors?
Five Arrows (Paris), Torreal, BioCity, and N2 Business Growth Fund have invested in Sygnature Discovery.
-
Who are Sygnature Discovery’s competitors?
Domainex, Rho, Verge Genomics, Recursion Pharmaceuticals, and X-37 are some of the 53 competitors of Sygnature Discovery.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
